{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:28:25Z","timestamp":1776871705507,"version":"3.51.2"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T00:00:00Z","timestamp":1627689600000},"content-version":"am","delay-in-days":303,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.neuropharm.2020.108251","type":"journal-article","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T11:23:18Z","timestamp":1595416998000},"page":"108251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Clinical potential of a rationally engineered enzyme for treatment of cocaine dependence: Long-lasting blocking of the psychostimulant, discriminative stimulus, and reinforcing effects of cocaine"],"prefix":"10.1016","volume":"176","author":[{"given":"Ting","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huimei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Guo","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2020.108251_bib1","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1038\/npp.2008.135","article-title":"Abstinence from chronic cocaine self-administration alters striatal dopamine systems in rhesus monkeys","volume":"34","author":"Beveridge","year":"2009","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"10.1016\/j.neuropharm.2020.108251_bib2","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1038\/sj.npp.1301666","article-title":"A cocaine hydrolase engineered from human butyrylcholinesterase selectively blocks cocaine toxicity and reinstatement of drug seeking in rats","volume":"33","author":"Brimijoin","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2020.108251_bib3","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cbi.2019.04.012","article-title":"Development of a long-acting Fc-fused cocaine hydrolase with improved yield of protein expression","volume":"306","author":"Chen","year":"2019","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.neuropharm.2020.108251_bib4","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1073\/pnas.1517713113","article-title":"Long-acting cocaine hydrolase for addiction therapy","volume":"113","author":"Chen","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2020.108251_bib5","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1021\/acschembio.6b00277","article-title":"Metabolic enzymes of cocaine metabolite benzoylecgonine","volume":"11","author":"Chen","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.neuropharm.2020.108251_bib6","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jpba.2016.11.024","article-title":"A quantitative LC-MS\/MS method for simultaneous determination of cocaine and its metabolites in whole blood","volume":"134","author":"Chen","year":"2017","journal-title":"J. Pharmaceut. Biomed. Anal."},{"key":"10.1016\/j.neuropharm.2020.108251_bib7","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/jcph.450","article-title":"Safety, pharmacokinetics, and pharmacodynamics of TV-1380, a novel mutated butyrylcholinesterase treatment for cocaine addiction, after single and multiple intramuscular injections in healthy subjects","volume":"55","author":"Cohen-Barak","year":"2015","journal-title":"J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.neuropharm.2020.108251_bib8","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/npp.2011.226","article-title":"Long-lasting effects of a PEGylated mutant cocaine esterase (CocE) on the reinforcing and discriminative stimulus effects of cocaine in rats","volume":"37","author":"Collins","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2020.108251_bib9","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/npp.2011.226","article-title":"Long\u2010lasting effects of a PEGylated mutant cocaine esterase (CocE) on the reinforcing and discriminative stimulus effects of cocaine in rats","volume":"37","author":"Collins","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2020.108251_bib10","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1124\/pr.115.011668","article-title":"Evaluation of the \"pipeline\" for development of medications for cocaine use disorder: a review of translational preclinical, human laboratory, and clinical trial research","volume":"68","author":"Czoty","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2020.108251_bib12","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1126\/science.1214463","article-title":"Abnormal brain structure implicated in stimulant drug addiction","volume":"335","author":"Ersche","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2020.108251_bib13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.drugalcdep.2016.05.019","article-title":"Placebo-controlled evaluation of a bioengineered, cocaine-metabolizing fusion protein, TV-1380 (AlbuBChE), in the treatment of cocaine dependence","volume":"166","author":"Gilgun-Sherki","year":"2016","journal-title":"Drug Alcohol Depend."},{"issue":"2","key":"10.1016\/j.neuropharm.2020.108251_bib14","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1586\/17512433.1.2.277","article-title":"Pharmacokinetic approaches to treatment of drug addiction","volume":"1","author":"Gorelick","year":"2008","journal-title":"Expet Rev. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108251_bib15","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.2165\/00003495-200464140-00004","article-title":"Agents in development for the management of cocaine abuse","volume":"64","author":"Gorelick","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.neuropharm.2020.108251_bib16","doi-asserted-by":"crossref","first-page":"7477","DOI":"10.1039\/c3ob41713a","article-title":"Substrate selectivity of high-activity mutants of human butyrylcholinesterase","volume":"11","author":"Hou","year":"2013","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.neuropharm.2020.108251_bib17","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1042\/BJ20140360","article-title":"Kinetic characterization of human butyrylcholinesterase mutants for hydrolysis of cocaethylene","volume":"460","author":"Hou","year":"2014","journal-title":"Biochem. J."},{"issue":"45","key":"10.1016\/j.neuropharm.2020.108251_bib18","doi-asserted-by":"crossref","first-page":"15057","DOI":"10.1021\/jp900963n","article-title":"Mechanism for cocaine blocking the transport of dopamine: insights from molecular modeling and dynamics simulations","volume":"113","author":"Huang","year":"2009","journal-title":"J. Phys. Chem. B"},{"issue":"5103","key":"10.1016\/j.neuropharm.2020.108251_bib19","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1126\/science.8456315","article-title":"Antibody-catalyzed degradation of cocaine","volume":"259","author":"Landry","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2020.108251_bib20","article-title":"Large scale purification of butyrylcholinesterase from human plasma suitable for injection into monkeys; a potential new therapeutic for protection against cocaine and nerve agent toxicity","volume":"3","author":"Lockridge","year":"2005","journal-title":"J. Med. Chem. Biol. Radiol. Def."},{"key":"10.1016\/j.neuropharm.2020.108251_bib21","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00213-007-0754-7","article-title":"Levo-tetrahydropalmatine attenuates cocaine self-administration and cocaine-induced reinstatement in rats","volume":"192","author":"Mantsch","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2020.108251_bib22","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1126\/science.1221691","article-title":"Wiping drug memories","volume":"336","author":"Milton","year":"2012","journal-title":"Science"},{"issue":"46","key":"10.1016\/j.neuropharm.2020.108251_bib23","doi-asserted-by":"crossref","first-page":"16656","DOI":"10.1073\/pnas.0507332102","article-title":"Computational redesign of human butyrylcholinesterase for anticocaine medication","volume":"102","author":"Pan","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2020.108251_bib24","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1369-1600.2011.00424.x","article-title":"Modification of pharmacokinetic and abuse-related effects of cocaine by human-derived cocaine hydrolase in monkeys","volume":"18","author":"Schindler","year":"2013","journal-title":"Addiction Biol."},{"key":"10.1016\/j.neuropharm.2020.108251_bib25","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1749-6632.2009.05148.x","article-title":"Regulation of the dopamine transporter: aspects relevant to psychostimulant drugs of abuse","volume":"1187","author":"Schmitt","year":"2010","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2020.108251_bib26","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.drugalcdep.2018.01.033","article-title":"TV-1380 attenuates cocaine-induced changes in cardiodynamic parameters in monkeys and reduces the formation of cocaethylene","volume":"188","author":"Shemesh-Darvish","year":"2018","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2020.108251_bib27","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/JCP.0000000000000347","article-title":"Assessment of pharmacokinetic and pharmacodynamic interactions between albumin-fused mutated butyrylcholinesterase and intravenously administered cocaine in recreational cocaine users","volume":"35","author":"Shram","year":"2015","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2020.108251_bib28","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2174\/187152731406150624122404","article-title":"Editorial: emerging targets for stimulant use disorders: where to invest in an era of constrained Resources?","volume":"14","author":"Skolnick","year":"2015","journal-title":"CNS Neurol. Disord. - Drug Targets"},{"issue":"3","key":"10.1016\/j.neuropharm.2020.108251_bib29","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/nprot.2006.167","article-title":"Using drug-discrimination techniques to study the abuse-related effects of psychoactive drugs in rats","volume":"1","author":"Solinas","year":"2006","journal-title":"Nat. Protoc."},{"issue":"2","key":"10.1016\/j.neuropharm.2020.108251_bib30","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1124\/mol.62.2.220","article-title":"Re-engineering butyrylcholinesterase as a cocaine hydrolase","volume":"62","author":"Sun","year":"2002","journal-title":"Mol. Pharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2020.108251_bib31","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S1385-299X(02)00185-X","article-title":"Jugular vein catheterization for repeated blood sampling in the unrestrained conscious rat","volume":"10","author":"Thrivikraman","year":"2002","journal-title":"Brain Res Brain Res Protoc"},{"key":"10.1016\/j.neuropharm.2020.108251_bib32","doi-asserted-by":"crossref","first-page":"9254","DOI":"10.1038\/s41598-020-66250-z","article-title":"Effects of cebranopadol on cocaine-induced hyperactivity and cocaine pharmacokinetics in rats","volume":"10","author":"Wei","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2020.108251_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108128","article-title":"Cebranopadol reduces cocaine self-administration in male rats: dose, treatment and safety considerations","volume":"172","author":"Wei","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2020.108251_bib34","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1038\/522S53a","article-title":"Quest for the quitting pill","volume":"522","author":"Willyard","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2020.108251_bib35","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1124\/mol.110.068494","article-title":"Design, preparation, and characterization of high-activity mutants of human butyrylcholinesterase specific for detoxification of cocaine","volume":"79","author":"Xue","year":"2011","journal-title":"Mol. Pharmacol."},{"issue":"1\u20133","key":"10.1016\/j.neuropharm.2020.108251_bib36","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.cbi.2010.01.004","article-title":"Characterization of a high-activity mutant of human butyrylcholinesterase against (-)-cocaine","volume":"187","author":"Yang","year":"2010","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.neuropharm.2020.108251_bib37","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1021\/acschemneuro.5b00001","article-title":"Molecular mechanism of HIV-1 Tat interacting with human dopamine transporter","volume":"6","author":"Yuan","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108251_bib38","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.4155\/fmc-2016-0138","article-title":"Computational modeling of human dopamine transporter structures, mechanism and its interaction with HIV-1 transactivator of transcription","volume":"8","author":"Yuan","year":"2016","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.108251_bib39","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/jcc.20241","article-title":"First-principle studies of intermolecular and intramolecular catalysis of protonated cocaine","volume":"26","author":"Zhan","year":"2005","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.neuropharm.2020.108251_bib40","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1021\/ja020850+","article-title":"Fundamental reaction mechanism for cocaine hydrolysis in human butyrylcholinesterase","volume":"125","author":"Zhan","year":"2003","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.neuropharm.2020.108251_bib41","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1042\/BJ20131100","article-title":"Kinetic characterization of high-activity mutants of human butyrylcholinesterase for the cocaine metabolite norcocaine","volume":"457","author":"Zhan","year":"2014","journal-title":"Biochem. J."},{"key":"10.1016\/j.neuropharm.2020.108251_bib42","doi-asserted-by":"crossref","first-page":"15303","DOI":"10.1038\/s41598-017-14105-5","article-title":"Clinical potential of an enzyme-based novel therapy for cocaine overdose","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2020.108251_bib43","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1038\/ncomms4457","article-title":"A highly efficient cocaine-detoxifying enzyme obtained by computational design","volume":"5","author":"Zheng","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuropharm.2020.108251_bib44","doi-asserted-by":"crossref","first-page":"9113","DOI":"10.1021\/bi1011628","article-title":"Design of high-activity mutants of human butyrylcholinesterase against (-)-cocaine: structural and energetic factors affecting the catalytic efficiency","volume":"49","author":"Zheng","year":"2010","journal-title":"Biochemistry"},{"issue":"36","key":"10.1016\/j.neuropharm.2020.108251_bib45","doi-asserted-by":"crossref","first-page":"12148","DOI":"10.1021\/ja803646t","article-title":"Most efficient cocaine hydrolase designed by virtual screening of transition states","volume":"130","author":"Zheng","year":"2008","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.neuropharm.2020.108251_bib46","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1039\/B716268E","article-title":"Structure-and-mechanism-based design and discovery of therapeutics for cocaine overdose","volume":"6","author":"Zheng","year":"2008","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.neuropharm.2020.108251_bib47","doi-asserted-by":"crossref","first-page":"515","DOI":"10.4155\/fmc.09.20","article-title":"Recent progress in protein drug design and discovery with a focus on novel approaches to the development of anti-cocaine medications","volume":"1","author":"Zheng","year":"2009","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.108251_bib48","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4155\/fmc.10.275","article-title":"Enzyme therapy approaches for treatment of drug overdose and addiction","volume":"3","author":"Zheng","year":"2011","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.108251_bib49","doi-asserted-by":"crossref","first-page":"125","DOI":"10.4155\/fmc.11.171","article-title":"Are pharmacokinetic approaches feasible for treatment of cocaine addiction and overdose?","volume":"4","author":"Zheng","year":"2012","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.108251_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1002610","article-title":"Modeling of pharmacokinetics of cocaine in human reveals the feasibility for development of enzyme therapies for drugs of abuse","volume":"8","author":"Zheng","year":"2012","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.neuropharm.2020.108251_bib51","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1039\/C9OB02762A","article-title":"Catalytic activities of cocaine hydrolases against the most toxic cocaine metabolite norcocaethylene","volume":"18","author":"Zheng","year":"2020","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.neuropharm.2020.108251_bib52","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1208\/s12248-020-00442-3","article-title":"Structure-based design and discovery of a long-acting cocaine hydrolase mutant with improved binding affinity to neonatal Fc receptor for treatment of cocaine abuse","volume":"22","author":"Zheng","year":"2020","journal-title":"AAPS J."},{"key":"10.1016\/j.neuropharm.2020.108251_bib53","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1208\/s12248-017-0167-4","article-title":"Effectiveness of a cocaine hydrolase for cocaine toxicity treatment in male and female rats","volume":"20","author":"Zheng","year":"2018","journal-title":"AAPS J."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390820303191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390820303191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:04:53Z","timestamp":1758438293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390820303191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":52,"alternative-id":["S0028390820303191"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108251","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical potential of a rationally engineered enzyme for treatment of cocaine dependence: Long-lasting blocking of the psychostimulant, discriminative stimulus, and reinforcing effects of cocaine","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108251","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108251"}}